Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 17 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced a licensing agreement with Lupin for co-marketing an innovative Semaglutide Injection in India. Under this agreement, Zydus will market the product under specific brand names while Lupin will have semi-exclusive rights to co-market it under their own brands. The partnership aims to enhance patient access to advanced therapies for diabetes and weight management.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases